skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Blinatumomab (Code C62528)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Blinatumomab

Definition: A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.

Display Name: Blinatumomab

Label: Blinatumomab

NCI Thesaurus Code: C62528 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3853839  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody
Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103

External Source Codes: 
CAS Registry Number 853426-35-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 487684
PDQ Open Trial Search ID 487684 (check for NCI PDQ open clinical trial info)
UMLS CUI C3853839

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
code C62528
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom